ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Intra-Cellular nabs nod for schizophrenia drug after FDA twists
December 31, 2019Intra-Cellular Therapies had quite a journey toward an FDA decision on its antipsychotic contender. It involved mixed clinical data, a canceled advisory committee meeting and a three-month review extension. -
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
September 16, 2019Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders ... -
Intra-Cellular Therapies Announces Positive Phase III Results
July 17, 2019Lumateperone achieves topline results in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.
Pharma Sources Insight January 2025
